Publications by authors named "S L Peters"
Background: The currently approved frontline treatments for diffuse pleural mesothelioma (DPM) are ipilimumab-nivolumab or platinum-pemetrexed. The addition of bevacizumab to chemotherapy improves overall survival (OS). While single-agent immunotherapy or chemotherapy-immunotherapy combinations are superior to chemotherapy monotherapy, there is a potential for synergistic triple combination of chemotherapy, bevacizumab, and immunotherapy.
View Article and Find Full Text PDFImmune-checkpoint inhibitors (ICIs) have transformed the treatment paradigm for advanced-stage squamous non-small-cell lung cancer (LUSC), a histological subtype associated with inferior outcomes compared with lung adenocarcinoma. However, only a subset of patients derive durable clinical benefit. In the first-line setting, multiple ICI regimens are available, including anti-PD-(L)1 antibodies as monotherapy, in combination with chemotherapy, or with an anti-CTLA4 antibody with or without chemotherapy.
View Article and Find Full Text PDFArticle Synopsis
- Human adenovirus type 5 (HAdV-5)-based oncolytic viruses have potential for cancer therapy, but face challenges like poor targeting and liver toxicity.
- Researchers created a modified HAdV-5 vector (HAdV-5-HexPos3_ΔCAR) that improves cancer cell targeting and reduces off-target effects, especially in liver tissues.
- The modified vector showed a significant increase in tumor presence while minimizing adverse effects, suggesting it could enhance the efficacy and safety of adenoviral cancer treatments.